Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says

Executive Summary

Novartis' irritable bowel syndrome awareness ads are too specific to Zelnorm to be considered "reminder" ads, FDA says in an untitled letter to the company
Advertisement

Related Content

Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
FDA Plays Up Police Role; “White Paper” Recaps Recent Enforcement Steps
Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Novartis Zelnorm Approval: FDA Accepts Overseas History, Active Surveillance
Advertisement
UsernamePublicRestriction

Register

PS042081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel